We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Application of urine C-peptide creatinine ratio in type 2 diabetic patients with different levels of renal function.
- Authors
Wan Zhou; Jie Li; Xiaojing Yuan; Wei Wang; Huanran Zhou; Haoqiang Zhang; Shandong Ye
- Abstract
Objective: This study aims to investigate the effect of single urine C peptide/creatinine (UCPCR) in assessing the islet b Cell function of type 2 diabetes mellitus (T2DM) patients with different renal function. Methods: A total of 85 T2DM patients were recruited in this study, all the patients were assigned to one group with estimated glomerular filtration rate (eGFR)=60 ml·min-1·1.73 m-2 and another group complicatedwith eGFR>60ml·min-1·1.73 m-2. Serum creatinine, urine creatinine, serum fasting C-peptide (FCP), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1C) and 24-hour urinary C-peptide (24hUCP) weremeasured. The modified homeostasis model assessment-islet β cell function [HOMA-islet (CP-DM)], the modified homeostasis model assessmentinsulin resistance [HOMA-IR(CP)] and UCPCR were calculated. Results: When compared with group eGFR =60 ml·min-1·1.73 m-2, the levels of UCPCR, FCP, the modified HOMA-IR(CP) and HOMA-islet (CP-DM) were promoted and the concentrations of HbA1C, FPG, creatinine were decreased in the patients of eGFR>60 ml·min-1·1.73 m-2 (P<0.05); FCP was uncorrelated with 24hUCP while associated with UCPCR in the patients of eGFR = 60 ml·min-1·1.73m-2; UCPCR was positively correlatedwith FCP andHOMA-IR(CP) in the T2DM patients with different levels of renal function; the cut-off (UCPCR = 1.13 nmol/g) had 88.37% sensitivity and 95.24% specificity [95% confidence interval (CI):0.919-0.997] for identifying severe insulin deficiency in T2DM patients[area under the curve (AUC) 0.978]. Conclusion: UCPCR can be used to evaluate islets β Cell function in T2DM patients with different renal function status.
- Subjects
KIDNEY physiology; CREATININE; PEOPLE with diabetes; TYPE 2 diabetes; GLYCOSYLATED hemoglobin; C-peptide
- Publication
Frontiers in Endocrinology, 2022, Vol 13, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2022.1052794